For example, in melanoma, mutations in JAK1/JAK2 (Janus Kinase 1/2) and B2M (beta-2-microglobulin) genes associated with acquired resistance to ICIs, and STK11/LKB1 mutations in KRAS mutated lung adenocarcinoma, have been documented [67,68]. This evidence concerns the gene JAK1 and lung adenocarcinoma.